Summary by Futu AI
On July 22, 2024, Novo Nordisk A/S, a global healthcare leader headquartered in Denmark, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over 12 months starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7 and August 5, 2024. Since the last update on July 15, Novo Nordisk has acquired an additional 186,967 B shares at an average price of DKK 941.45, totaling DKK 175,979,457. Overall, from the beginning of the buyback period on February 6, 2024, the company has repurchased 10,619,037 B shares at an average price of DKK 878.31 per share, amounting to DKK 9,326,780,889. These transactions have increased the company's treasury shares to 11,984,827 B shares, which is 0.3% of the share capital. Novo Nordisk's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange under the symbols 'Novo-B' and 'NVO', respectively.